Posted by Michael Wonder on 29 Apr 2020
Erytech Pharma granted U.S. FDA fast track designation for eryaspase in second-line pancreatic cancer
28 April 2020 - Fast track designation for eryaspase underscores the urgent need for potential new treatment options for patients with second line metastatic pancreatic cancer.
Erytech Pharma announced today that the U.S. FDA has granted eryaspase fast track designation for the development of a second-line treatment of patients with metastatic pancreatic cancer.
Eryaspase, is being evaluated in a Phase 3 trial (TRYbeCA-1) in second-line metastatic pancreatic cancer in 11 countries in Europe and the United States.
